Amneal Pharmaceuticals (AMRX) Income from Non-Controlling Interests (2017 - 2026)

Amneal Pharmaceuticals' Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• On a quarterly basis, Income from Non-Controlling Interests rose 26.73% year-over-year to $15.7 million in Q1 2026; TTM through Mar 2026 was $59.2 million, a 30.19% increase from a year earlier, with the FY2025 full-year figure at $55.9 million, up 29.91% from the prior year.
• Income from Non-Controlling Interests climbed to $15.7 million in Q1 2026 per AMRX's latest filing, from $14.5 million in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $17.8 million in Q2 2023 and bottomed at -$119.3 million in Q2 2022.
• The 5-year median for Income from Non-Controlling Interests is $10.8 million (2024), against an average of $1.5 million.
• Across the five-year window, Income from Non-Controlling Interests plunged 776.0% in 2022 and jumped 5034.11% in 2023, its largest moves.
• Year by year, Income from Non-Controlling Interests stood at -$1.5 million in 2022, then soared by 447.87% to $5.3 million in 2023, then jumped by 94.89% to $10.3 million in 2024, then soared by 40.22% to $14.5 million in 2025, then grew by 8.6% to $15.7 million in 2026.
• Per Business Quant, the three latest AMRX Income from Non-Controlling Interests figures stand at $15.7 million (Q1 2026), $14.5 million (Q4 2025), and $15.8 million (Q3 2025).